Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Annexon to Present Significant Phase 3 Results of ANX005 in Guillain-Barré Syndrome at PNS Annual Meeting; Potential to be First Targeted Therapy for GBS

Author: Benzinga Newsdesk | June 18, 2024 08:16am

Posted In: ANNX